Acelyrin, Inc. (SLRN) Stock Analysis & Investment Frameworks
Acelyrin, Inc. (SLRN) stock analysis on Invetso. Review Acelyrin, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Acelyrin, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Acelyrin, Inc. Key Financial Metrics
- Market Cap: $229.17M
- Revenue: $N/A
- ROE: -44.54%
- ROIC: -68.08%
- Dividend Yield: N/A
About Acelyrin, Inc.
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.
Acelyrin, Inc. Investment Frameworks
Invetso analyzes Acelyrin, Inc. (SLRN) across the following frameworks:
- Acelyrin, Inc. 10Y Growth Potential
- Acelyrin, Inc. Scenario Analysis
- Acelyrin, Inc. Risks & Opportunities
- Acelyrin, Inc. Economic Moat
- Acelyrin, Inc. Business Model
- Acelyrin, Inc. Management
- Acelyrin, Inc. SWOT Analysis
- Acelyrin, Inc. Porter's 5 Forces
- Acelyrin, Inc. PESTLE Analysis
- Acelyrin, Inc. ESG Analysis